Freites-Nunez D, Leon L, Toledano E, Candelas G, Martinez C, Rodriguez-Laguna M
Ther Adv Musculoskelet Dis. 2024; 16:1759720X241273083.
PMID: 39219744
PMC: 11366104.
DOI: 10.1177/1759720X241273083.
Hen O, Harrison S, De Marco G, Marzo-Ortega H
Ther Adv Musculoskelet Dis. 2024; 16:1759720X241266727.
PMID: 39071239
PMC: 11283661.
DOI: 10.1177/1759720X241266727.
Al-Homood I, Al Ghanim N, Fatani M, Hussein A, Alolaiwi A, Abualiat A
Clin Rheumatol. 2024; 43(3):879-894.
PMID: 38217738
PMC: 10876726.
DOI: 10.1007/s10067-024-06867-x.
Jawad I, Nisar M
Eur J Rheumatol. 2022; 9(2):100-103.
PMID: 35156631
PMC: 10176215.
DOI: 10.5152/eurjrheum.2021.21027.
Baraliakos X, Tsiami S, Vijayan S, Jung H, Barkham N
Clin Case Rep. 2022; 10(1):e05205.
PMID: 35079380
PMC: 8777045.
DOI: 10.1002/ccr3.5205.
Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists.
Raine T, Gkini M, Irving P, Kaul A, Korendowych E, Laws P
BioDrugs. 2021; 35(2):187-199.
PMID: 33635522
PMC: 7952361.
DOI: 10.1007/s40259-020-00464-5.
Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting.
Camargo M, Barros B, Fulone I, Silva M, Silveira M, de Camargo I
Front Pharmacol. 2019; 10:965.
PMID: 31572173
PMC: 6749844.
DOI: 10.3389/fphar.2019.00965.
Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study.
Clunie G, McInnes I, Barkham N, Marzo-Ortega H, Patel Y, Gough A
Rheumatol Adv Pract. 2019; 2(2):rky042.
PMID: 31431979
PMC: 6649900.
DOI: 10.1093/rap/rky042.
(Un)Spoken realities of living with axial spondyloarthritis: a qualitative study focused on couple experiences.
Raybone K, Family H, Sengupta R, Jordan A
BMJ Open. 2019; 9(7):e025261.
PMID: 31272972
PMC: 6615774.
DOI: 10.1136/bmjopen-2018-025261.
Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study.
Kivitz A, Nash P, Tahir H, Everding A, Mann H, Kaszuba A
Rheumatol Ther. 2019; 6(3):393-407.
PMID: 31228101
PMC: 6702584.
DOI: 10.1007/s40744-019-0163-5.
French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults.
Amatore F, Villani A, Tauber M, Viguier M, Guillot B
J Eur Acad Dermatol Venereol. 2019; 33(3):464-483.
PMID: 30793796
PMC: 6593704.
DOI: 10.1111/jdv.15340.
Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial.
Mease P, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S
RMD Open. 2018; 4(2):e000723.
PMID: 30167329
PMC: 6109799.
DOI: 10.1136/rmdopen-2018-000723.
Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic.
Luchetti M, Benfaremo D, Campanati A, Molinelli E, Ciferri M, Cataldi S
Clin Rheumatol. 2018; 37(10):2741-2749.
PMID: 30056525
DOI: 10.1007/s10067-018-4238-4.
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.
Gladman D, Kavanaugh A, Gomez-Reino J, Wollenhaupt J, Cutolo M, Schett G
RMD Open. 2018; 4(1):e000669.
PMID: 30018799
PMC: 6045740.
DOI: 10.1136/rmdopen-2018-000669.
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK.
Buchanan V, Sullivan W, Graham C, Miles L, Jugl S, Gunda P
Pharmacoeconomics. 2018; 36(7):867-878.
PMID: 29797187
PMC: 5999172.
DOI: 10.1007/s40273-018-0674-x.
Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review.
Kingsley G, Scott D
Psoriasis (Auckl). 2018; 5:71-81.
PMID: 29387584
PMC: 5683113.
DOI: 10.2147/PTT.S52893.
Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
Schulze-Koops H, Skapenko A
Rheumatology (Oxford). 2017; 56(suppl_4):iv30-iv48.
PMID: 28903543
PMC: 5850807.
DOI: 10.1093/rheumatology/kex277.
Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases.
Schulze-Koops H
Rheumatology (Oxford). 2017; 56(suppl_4):iv1-iv3.
PMID: 28903541
PMC: 5850353.
DOI: 10.1093/rheumatology/kex275.
Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?.
Patton T, Bojke L, Walton M, Manca A, Helliwell P
Clin Rheumatol. 2017; 36(8):1803-1810.
PMID: 28612241
PMC: 5519654.
DOI: 10.1007/s10067-017-3703-9.
Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control.
Furst D, Tran M, Sullivan E, Pike J, Piercy J, Herrera V
Clin Rheumatol. 2017; 36(9):2045-2054.
PMID: 28238086
PMC: 5554474.
DOI: 10.1007/s10067-017-3578-9.
